Drug General Information
Drug ID
Former ID
Drug Name
Drug Type
Small molecular drug
Indication Mantle cell lymphoma [ICD9: 200.4, 202.8, 203.0, 208.9; ICD10:C81-C86, C85.7, C90.0, C91-C95] Phase 2 [533193]
Nicholas Piramal


Canonical SMILES
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Cell division protein kinase 9 Target Info Inhibitor [537564]
Cell division control protein 2 homolog Target Info Inhibitor [537564]
Cell division protein kinase 4 Target Info Inhibitor [537564]
KEGG Pathway Transcriptional misregulation in cancerhsa04110:Cell cycle
Oocyte meiosis
p53 signaling pathway
Gap junction
Progesterone-mediated oocyte maturation
Herpes simplex infection
Epstein-Barr virus infection
Viral carcinogenesishsa04110:Cell cycle
PI3K-Akt signaling pathway
Tight junction
T cell receptor signaling pathway
Hepatitis B
HTLV-I infection
Pathways in cancer
Viral carcinogenesis
Pancreatic cancer
Bladder cancer
Chronic myeloid leukemia
Small cell lung cancer
Non-small cell lung cancer
NetPath Pathway EGFR1 Signaling PathwayNetPath_21:RANKL Signaling PathwayNetPath_11:TCR Signaling Pathway
EGFR1 Signaling Pathway
RANKL Signaling Pathway
Pathway Interaction Database p73 transcription factor network
E2F transcription factor network
PLK1 signaling events
AP-1 transcription factor network
FOXM1 transcription factor network
Retinoic acid receptors-mediated signalingsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Validated targets of C-MYC transcriptional activation
ATF-2 transcription factor network
Regulation of retinoblastoma protein
Reactome SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptionR-HSA-110056:MAPK3 (ERK1) activation
E2F mediated regulation of DNA replication
G0 and Early G1
Cyclin B2 mediated events
Golgi Cisternae Pericentriolar Stack Reorganization
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
Regulation of APC/C activators between G1/S and early anaphase
Phosphorylation of the APC/C
Phosphorylation of Emi1
Condensation of Prophase Chromosomes
MASTL Facilitates Mitotic Progression
Resolution of Sister Chromatid Cohesion
Condensation of Prometaphase Chromosomes
Regulation of PLK1 Activity at G2/M Transition
Activation of NIMA Kinases NEK9, NEK6, NEK7
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Recruitment of NuMA to mitotic centrosomes
Depolymerisation of the Nuclear Lamina
Anchoring of the basal body to the plasma membrane
MAPK6/MAPK4 signaling
G1/S-Specific Transcription
Cyclin A/B1 associated events during G2/M transition
G2/M DNA replication checkpoint
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-2559580:Oxidative Stress Induced Senescence
Senescence-Associated Secretory Phenotype (SASP)
Oncogene Induced Senescence
RMTs methylate histone arginines
Transcriptional regulation of white adipocyte differentiation
Ubiquitin-dependent degradation of Cyclin D1
Cyclin D associated events in G1
Meiotic recombination
WikiPathways Cardiac Hypertrophic Response
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
Host Interactions of HIV factors
HIV Life Cycle
IL-9 Signaling Pathway
RNA Polymerase II Transcription
MicroRNAs in cardiomyocyte hypertrophyWP707:DNA Damage Response
G1 to S cell cycle control
TGF beta Signaling Pathway
PPAR Alpha Pathway
MAP kinase activation in TLR cascade
RAF/MAP kinase cascade
Mitotic Prophase
Mitotic Prometaphase
ATM Signaling Pathway
Retinoblastoma (RB) in Cancer
Spinal Cord Injury
Prostate Cancer
Regulation of Microtubule Cytoskeleton
Integrated Cancer pathway
Mitotic G2-G2/M phases
Mitotic G1-G1/S phases
Cell Cycle
APC/C-mediated degradation of cell cycle proteins
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
Ovarian Infertility Genes
Bladder Cancer
S Phase
Transcriptional Regulation of White Adipocyte Differentiation
Meiotic Recombination
Integrated Pancreatic Cancer Pathway
Signaling Pathways in Glioblastoma
TSH signaling pathway
Integrated Breast Cancer Pathway
miRNA Regulation of DNA Damage Response
Ref 533193A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):392-7.
Ref 537564Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.